Advancing Biotechnology Research

Antitope is pioneering a new generation of immunogenicity testing, antibody humanization and protein engineering technologies.

Our mission is to apply these technologies to create improved non-immunogenic biologics. Formed in 2004, Antitope provides proprietary technologies as a comprehensive service for the preclinical prediction of clinical immunogenicity,  and for the generation of humanized antibodies, therapeutic proteins and recombinant vaccines. To date, we have entered into multiple agreements with pharmaceutical and biotechnology companies worldwide to apply our technologies for the development of improved biologics.
 

News & Press

26.01.2010
Antitope Ltd. today announced a research agreement with Agence Nationale de Recherches sur le SIDA et les hepatitives virales (ANRS, France), INSERM (France) and Baylor Research Institute (BRI, Dallas, Texas USA)
Cambridge UK, January 2010 - Antitope Ltd. today announced a research agreement with Agence Nationale de Recherches sur le SIDA et les hepatitives virales (ANRS,...
26.01.2010
Antitope Announces Research Agreement with Emory University
26th January 2010 - Antitope Ltd. (UK) today announced a research agreement with Emory University, Atlanta (USA) for the development of an antibody therapeutic for H1N1...